• Mycophenolate Mofetil May Be Alternative to Cyclophosphamide, Analysis Shows
  • First Part of IFX-1 Trial in AAV Patients in EU Fully Enrolled, InflaRx Says
  • COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say
  • Eurordis Urges Expansion of Newborn Screening Initiatives Across Europe
  • Unity and EU-wide Efforts Focus of Online Rare Disease Meeting
  • Request for FDA Approval of Avacopan Likely by Mid-year, ChemoCentryx Says
  • Rare Diseases Clinical Research Network Opens Online Survey on COVID-19
  • Hydralazine Causes Rare Case of AAV with Severe Respiratory, Kidney Failure, Study Reports
  • AAV Linked to Inflammation, Thickening of Brain Membranes in Case Study
  • NORD Webinar Outlines COVID-19 Response on Financial, Policy Fronts
  • Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak
  • Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say